

HEPATITIS AND PREGNANCY

OSAMA M WARDA MD

Prof. OBS/GYN

Mansoura University

Liver disease in pregnancy


- Three possible etiologic relationship:
- 1. The patient has a liver disease induced by pregnancy; acute fatty liver disease of pregnancy, intrahepatic cholestasis of pregnancy, hyperemesis gravidarum, preeclampsia or HELLP syndrome


Liver disease in pregnancy

- Three possible etiologic relationship:
- 2. The patient has developed a new liver disease during pregnancy mainly hepatobiliary disease.
- 3. The patient has preexisting chronic liver disease, mainly chronic hepatitis B and C

Our topic will discuss this last issue

Geographic Distribution of Chronic HBV Infection





Hepatitis and pregnancy

- In women with severe chronic liver disease, pregnancy is unusual
- ☑ the chronic liver disease is associated with anovulatory state.

Cirrhosis and portal hypertension

- The main problem for a pregnant woman with cirrhosis and portal hypertension include worsening jaundice with progressive liver failure, ascites, and hepatic coma.
- The increase in total blood volume associated with pregnancy may worsen pre-existing portal hypertension and variceal hemorrhage during pregnancy and labor has been described, but is a rare situation

Cirrhosis and portal hypertension

- Women with known cirrhosis who desire pregnancy should be endoscoped to look for varices before pregnancy.
- If present, patients should be informed of the increased risk with pregnancy

Cirrhosis and portal hypertension

- Patients at high risk for variceal bleeding should be considered for primary prophylaxis with non-selective beta blockers (eg propranolol or nadolol)
- Newborns should be monitored during the first days of life because of risks of hypoglycemia and bradycardia.

Complete evaluation of the patient:

- clinical examination, liver tests, prothrombine time, albumine, HBV-DNA, HCV-RNA
- if you suspect a cirrhosis, perform an upper GI endoscopy to look for esophageal varices.

- Pregnancy is well tolerated by women who are chronic carriers of hepatitis B
- The placenta forms an excellent barrier against transmission of this large virus and intrauterine infection is rare.

- The major problem for women who are chronic carriers of HBV is the risk of maternal to infant (vertical) transmission at delivery due to exposure to maternal blood in the birth canal.

-Routine prenatal screening of all pregnant women for HBsAg and universal hepatitis B vaccination of all newborns at birth is the standard of care.

 Transmission at birth is more likely if the mother is: Hbe Ag positive B or has high circulating levels of HBV-DNA.


- Active (vaccine) and passive (HBIG): immunization interrupts transmission in over 90 % What could be proposed to try to reach 100 %?

Lamivudine during pregnancy

A small study has been performed in Taiwan in women becoming pregnant during a treatment with lamivudine: some agreed to continue the treatment during the pregnancy: $\rightarrow \rightarrow \rightarrow$

- the treatment was safe for the baby: no increase of stillbirths or premature delivery
- the protection reached 100 %

Outcome of Hepatitis B Virus Infection by Age at Infection



Prevalence of Hepatitis C in pregnant women (anti-HCV +)

Seri al	Countery	%
1	Egypt	15.8
2	Pakistan	3.2
3	Burkina Faso	1.5*
4	Ivory Coast	1*
5	USA	1
6	Switzerland	0.7
*	Higher incidence in HIV + pregnant women	

Hepatitis C and pregnancy

- 56 % of 266 women with elevated ALAT at the beginning of pregnancy,
- 7% at third trimester and again
- 55% 6 months after delivery (Conte D,
- Hepatology 2000)
- Viral load increased in third trimester (Gervais A, J Hepatol 2000)

(Mother To Child Transmission MTCT)

- 442 / 25 654 (1.7 %) pregnant women with positive anti-HCV antibodies
- 403 children followed for 28 months
- All children had positive anti-HCV antibodies at birth
- All children HCV-RNA negative lost anti-HCV antibodies in 20 months

(Resti M. BMJ 1998; 317:437-441)

(Mother To Child Transmission MTCT)

- 0 / 128 children born of HCV-RNA negative mother acquired infection
- 13 / 275 children of HCV-RNA positive mother acquired infection
- 6 were HCV-RNA positive at birth
- transmission rate : 5 % (3 to 7 %)
- 2.5 % before birth
- 2.5 % during first 6 months

(Resti M. BMJ 1998; 317:437-441)

(Mother To Child Transmission MTCT)

Risk of transmission is not different according to:

- Mode of delivery
- Viral load of mother
- Feeding type of child
- Do consider avoiding forceps

(expert opinion)

(Mother To Child Transmission MTCT)

- Cesarean versus Vaginal
- **Cochrane Database of Systematic Reviews 2006:**
- No RC trials, only observational studies
- Cesarean cannot be recommended (in HIV-)
- Factors that may increase risk of MTCT
- Viral load > 105 copies
- ALT > 110 u/l
- Blood loss at delivery > 500 g

(Hayashida A. J Obst & Gynecol Research 33(4):417,2007)

(Mother To Child Transmission MTCT)

- Rate of MTCT:
- **Detection**: at 2 months VHC-RNA

at 18 months anti-VHC

 $\rightarrow \rightarrow$ on average 5 %

CDC 3.8 % in **HIV**- ve and 25 % in HIV +ve

HCV - PCR testing

Predictive value

Children with low proportion of +ve PCR results (≤ 75% of time) more likely to clear HCV than those with high proportion of positive PCR results (P < .0001)

36.5% vs 5.6%; OR, 9.77 (95% CI, 2.92-32.67)

- Children with high proportion of +ve PCR results more likely to have positive results in:
 - Years 2 and 3: adjusted OR, 3.59 (P < .01)
 - Year 2 and older: adjusted OR, 2.92 (P < .03)

(European Paediatric Hepatitis C Virus Network. Clin Infect Dis. 2005;41:45-51.)

Conclusion

Among children with vertically acquired HCV:

~ 20% clear the virus

~ 50% develop chronic asymptomatic infection

European Paediatric Hepatitis C Virus Network. Clin Infect Dis. 2005;41:45-51.

Conclusion

- Low viral activity within first year of life associated with subsequent viral clearance
- Hepatomegaly most common clinical symptom observed
- Hepatomegaly, persistent viremiaare common in HCV/HIV- co-infected children

(European Paediatric Hepatitis C Virus Network. Clin Infect Dis. 2005;41:45-51).

ACOG RECOMMENDATIONS

(2007refined 2012)

- Levels of Recommendation
- Level A Recommendations are based on good and consistent scientific evidence.
- Level B Recommendations are based on limited or inconsistent scientific evidence.
- Level C Recommendations are based primarily on consensus and expert opinion.

ACOG-Level A recommendations

- Routine prenatal screening of all pregnant women by hepatitis B surface antigen (HBsAg) testing is recommended.
- Newborns born to hepatitis B carriers should receive combined immunoprophylaxis consisting of hepatitis B immune globulin (HBIG) and hepatitis B vaccine within 12 hours of birth.

ACOG-Level A recommendations

Hepatitis B infection is a preventable disease, and all at-risk individuals, particularly health care workers, should be vaccinated.

All infants should receive the hepatitis B vaccine series as part of the recommended childhood immunization schedule.

ACOG-Level A recommendations

- Breastfeeding is not contraindicated in:
- women with hepatitis A virus (HAV) infection with appropriate hygienic precautions,
- in those chronically infected with hepatitis B if the infant receives HBIG passive prophylaxis and vaccine active prophylaxis,
- or in women with hepatitis C virus (HCV) infection.

ACOG-Level B recommendations

- Routine prenatal HCV screening is **not** recommended; however, women with significant risk factors for infection should be offered antibody screening.
- Route of delivery has **not** been shown to influence the risk of vertical HCV transmission, and cesarean delivery should be reserved for obstetric indications in women with HCV infection.

ACOG-Level C recommendations

The risk of transmission of hepatitis B associated with amniocentesis is **low**.

Susceptible pregnant women who are at risk for hepatitis B infections should be specifically targeted for vaccination.

APPENDIX

- Levels of Recommendation
- Level A Recommendations are based on good and consistent scientific evidence.
- Level B Recommendations are based on limited or inconsistent scientific evidence.
- Level C Recommendations are based primarily on consensus and expert opinion.

APPENDIX-2

Grades of Evidence

- Evidence obtained from at least one properly designed randomized controlled trial.
- **II-1** Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case—control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

